Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) CEO Buys $24,780.00 in Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) CEO Jared Kelly bought 29,500 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was bought at an average price of $0.84 per share, for a total transaction of $24,780.00. Following the completion of the purchase, the chief executive officer directly owned 109,000 shares of the company’s stock, valued at $91,560. The trade was a 37.11% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jared Kelly also recently made the following trade(s):

• On Wednesday, February 11th, Jared Kelly purchased 5,600 shares of Oncolytics Biotech stock. The shares were purchased at an average price of $0.84 per share, with a total value of $4,704.00.

Oncolytics Biotech Stock Up 27.0%

ONCY stock opened at $1.06 on Monday. The stock has a market cap of $112.52 million, a PE ratio of -3.79 and a beta of 0.99. The firm’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.07. Oncolytics Biotech Inc. has a fifty-two week low of $0.33 and a fifty-two week high of $1.51.

Institutional Investors Weigh In On Oncolytics Biotech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONCY. Scientech Research LLC acquired a new stake in Oncolytics Biotech in the third quarter worth approximately $25,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Oncolytics Biotech during the 4th quarter valued at $29,000. Ground Swell Capital LLC bought a new stake in shares of Oncolytics Biotech in the 4th quarter worth $30,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Oncolytics Biotech in the fourth quarter valued at $44,000. Finally, Tocqueville Asset Management L.P. bought a new position in Oncolytics Biotech during the fourth quarter valued at about $63,000. Institutional investors own 6.82% of the company’s stock.

Analyst Upgrades and Downgrades

ONCY has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. Wall Street Zen downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, HC Wainwright boosted their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.25.

Key Stories Impacting Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.